Prediction of factor Xa inhibitors by machine learning methods

Journal of Molecular Graphics and Modelling

Volumn 26, Issue 2, 2007, Pages 505-518

  Lin, H H ^a   Han, L Y ^a   Yap, C W ^a   Xue, Y ^b   Liu, X H ^a   Zhu, F ^a   Chen, Y Z ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Anticoagulation; Coagulation; Factor Xa (FXa); Inhibitor; Machine learning; Molecular descriptors; Non inhibitor; Support vector machine (SVM); Thrombotic disease

Indexed keywords

COAGULATION; MOLECULAR DYNAMICS; NEURAL NETWORKS; SUPPORT VECTOR MACHINES;

ANTICOAGULATION; FACTOR XA (FXA); MOLECULAR DESCRIPTORS; THROMBOTIC DISEASES;

ENZYME INHIBITION;

BLOOD CLOTTING FACTOR 10A INHIBITOR;

ACCURACY; ARTICLE; ARTIFICIAL NEURAL NETWORK; DRUG STRUCTURE; MACHINE LEARNING; PREDICTION; PRIORITY JOURNAL; SUPPORT VECTOR MACHINE;

ARTIFICIAL INTELLIGENCE; ENZYME INHIBITORS; FACTOR XA; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548349206     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2007.03.003     Document Type: Article

References (102)

1. Furie B., and Furie B.C. The molecular basis of blood coagulation. Cell 53 4 (1988) 505-518
2. Broze Jr. G.J. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul. Fibrinol. 6 Suppl 1 (1995) S7-S13
3. Witting J.I., Bourdon P., Brezniak D.V., Maraganore J.M., and Fenton II J.W. Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem. J. 283 Pt 3 (1992) 737-743
4. Bona R.D., Hickey A.D., and Wallace D.M. Efficacy and safety of oral anticoagulation in patients with cancer. Thromb. Haemost. 78 1 (1997) 137-140
5. Kontogiorgis C.A., and Hadjipavlou-Litina D. Current trends in quantitative structure activity relationships on FXa inhibitors: evaluation and comparative analysis. Med. Res. Rev. 24 6 (2004) 687-747
6. Han Q., Dominguez C., Stouten P.F., Park J.M., Duffy D.E., Galemmo Jr. R.A., Rossi K.A., Alexander R.S., Smallwood A.M., Wong P.C., et al. Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors. J. Med. Chem. 43 23 (2000) 4398-4415
7. Willardsen J.A., Dudley D.A., Cody W.L., Chi L., McClanahan T.B., Mertz T.E., Potoczak R.E., Narasimhan L.S., Holland D.R., Rapundalo S.T., et al. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa. J. Med. Chem. 47 16 (2004) 4089-4099
8. Haginoya N., Kobayashi S., Komoriya S., Yoshino T., Nagata T., Hirokawa Y., and Nagahara T. Design, synthesis, and biological activity of non-amidine factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units. Bioorg. Med. Chem. 12 21 (2004) 5579-5586
9. Sato K., Kaku S., Hirayama F., Koshio H., Matsumoto Y., Kawasaki T., and Iizumi Y. Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time. Eur. J. Pharmacol. 352 1 (1998) 59-63
10. Wong P.C., Quan M.L., Crain E.J., Watson C.A., Wexler R.R., and Knabb R.M. Nonpeptide factor Xa inhibitors. I. Studies with SF303 and SK549, a new class of potent antithrombotics. J. Pharmacol. Exp. Ther. 292 1 (2000) 351-357
11. Phillips G.B., Buckman B.O., Davey D.D., Eagen K.A., Guilford W.J., Hinchman J., Ho E., Koovakkat S., Liang A., Light D.R., et al. Discovery of N-[2-[5-[amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycin e (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa. J. Med. Chem. 41 19 (1998) 3557-3562
12. Leung D., Abbenante G., and Fairlie D.P. Protease inhibitors: current status and future prospects. J. Med. Chem. 43 3 (2000) 305-341
13. Shrader W.D., Young W.B., Sprengeler P.A., Sangalang J.C., Elrod K., and Carr G. Neutral inhibitors of the serine protease factor Xa. Bioorg. Med. Chem. Lett. 11 14 (2001) 1801-1804
14. Murcia M., and Ortiz A.R. Virtual screening with flexible docking and COMBINE-based models. Application to a series of factor Xa inhibitors. J. Med. Chem. 47 4 (2004) 805-820
15. Krovat E.M., Fruhwirth K.H., and Langer T. Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa. J. Chem. Inf. Model 45 1 (2005) 146-159
16. Fontaine F., Pastor M., Zamora I., and Sanz F. Anchor-GRIND: filling the gap between standard 3D QSAR and the GRid-INdependent descriptors. J. Med. Chem. 48 7 (2005) 2687-2694
17. Jorissen R.N., and Gilson M.K. Virtual screening of molecular databases using a support vector machine. J. Chem. Inf. Model 45 3 (2005) 549-561
18. Perez J.J. Managing molecular diversity. Chem. Soc. Rev. 34 2 (2005) 143-152
19. Zernov V.V., Balakin K.V., Ivaschenko A.A., Savchuk N.P., and Pletnev I.V. Drug discovery using support vector machines. The case studies of drug-likeness, agrochemical-likeness, and enzyme inhibition predictions. J. Chem. Inform. Comp. Sci. 43 6 (2003) 2048-2056
20. Byvatov E., Fechner U., Sadowski J., and Schneider G. Comparison of support vector machine and artificial neural network systems for drug/nondrug classification. J. Chem. Inform. Comp. Sci. 43 6 (2003) 1882-1889
21. Xue Y., Yap C.W., Sun L.Z., Cao Z.W., Wang J.F., and Chen Y.Z. Prediction of p-glycoprotein substrates by support vector machine approach. J. Chem. Inform. Comp. Sci. 44 4 (2004) 1497-1505
22. Doniger S., Hofman T., and Yeh J. Predicting CNS permeability of drug molecules: comparison of neural network and support vector machine algorithms. J. Comput. Biol. 9 6 (2002) 849-864
23. He L., Jurs P.C., Custer L.L., Durham S.K., and Pearl G.M. Predicting the genotoxicity of polycyclic aromatic compounds from molecular structure with different classifiers. Chem. Res. Toxicol. 16 12 (2003) 1567-1580
24. Snyder R.D., Pearl G.S., Mandakas G., Choy W.N., Goodsaid F., and Rosenblum I.Y. Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules. Environ. Mol. Mutagen. 43 3 (2004) 143-158
25. Yap C.W., Cai C.Z., Xue Y., and Chen Y.Z. Prediction of torsade-causing potential of drugs by support vector machine approach. Toxicol. Sci. 79 1 (2004) 170-177
26. Yap C.W., and Chen Y.Z. Quantitative structure-pharmacokinetic relationships for drug distribution properties by using general regression neural network. J. Pharm. Sci. 94 1 (2004) 153-168
27. Xue Y., Li Z.R., Yap C.W., Sun L.Z., Chen X., and Chen Y.Z. Effect of molecular descriptor feature selection in support vector machine classification of pharmacokinetic and toxicological properties of chemical agents. J. Chem. Inform. Comp. Sci. 44 5 (2004) 1630-1638
28. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., and Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138 3 (1997) 863-870
29. Branham W.S., Dial S.L., Moland C.L., Hass B.S., Blair R.M., Fang H., Shi L., Tong W., Perkins R.G., and Sheehan D.M. Phytoestrogens and mycoestrogens bind to the rat uterine estrogen receptor. J. Nutr. 132 4 (2002) 658-664
30. Johnson R.A., and Wichern D.W. Applied Multivariate Statistical Analysis (1982), Prentice Hall, Englewood Cliffs, NJ
31. Specht D.F. Probabilistic neural networks. Neural Netw. 3 1 (1990) 109-118
32. Quinlan J.R. C4.5: Programs for Machine Learning (1993), Morgan Kaufmann, San Mateo, CA
33. Vapnik V.N. The Nature of Statistical Learning Theory (1995), Springer, New York
34. Burges C.J.C. A tutorial on support vector machines for pattern recognition. Data Mining Knowl. Discov. 2 2 (1998) 127-167
35. Arnaiz D.O., Zhao Z., Liang A., Trinh L., Witlow M., Koovakkat S.K., and Shaw K.J. Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors. Bioorg. Med. Chem. Lett. 10 9 (2000) 957-961
36. Becker M.R., Ewing W.R., Davis R.S., Pauls H.W., Ly C., Li A., Mason H.J., Choi-Sledeski Y.M., Spada A.P., Chu V., et al. Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors. Bioorg. Med. Chem. Lett. 9 18 (1999) 2753-2758
37. Buckman B.O., Mohan R., Koovakkat S., Liang A., Trinh L., and Morrissey M.M. Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors. Bioorg. Med. Chem. Lett. 8 16 (1998) 2235-2240
38. Choi-Sledeski Y.M., McGarry D.G., Green D.M., Mason H.J., Becker M.R., Davis R.S., Ewing W.R., Dankulich W.P., Manetta V.E., Morris R.L., et al. Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization. J. Med. Chem. 42 18 (1999) 3572-3587
39. Czekaj M., Klein S.I., Guertin K.R., Gardner C.J., Zulli A.L., Pauls H.W., Spada A.P., Cheney D.L., Brown K.D., Colussi D.J., et al. Optimization of the beta-aminoester class of factor Xa inhibitors. Part 1. P(4) and side-chain modifications for improved in vitro potency. Bioorg. Med. Chem. Lett. 12 12 (2002) 1667-1670
40. Ewing W.R., Becker M.R., Manetta V.E., Davis R.S., Pauls H.W., Mason H., Choi-Sledeski Y.M., Green D., Cha D., Spada A.P., et al. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. J. Med. Chem. 42 18 (1999) 3557-3571
41. Fevig J.M., Cacciola J., Alexander R.S., Knabb R.M., Lam G.N., Wong P.C., and Wexler R.R. Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa. Bioorg. Med. Chem. Lett. 8 22 (1998) 3143-3148
42. Gabriel B., Stubbs M.T., Bergner A., Hauptmann J., Bode W., Sturzebecher J., and Moroder L. Design of benzamidine-type inhibitors of factor Xa. J. Med. Chem. 41 22 (1998) 4240-4250
43. Galemmo Jr. R.A., Maduskuie T.P., Dominguez C., Rossi K.A., Knabb R.M., Wexler R.R., and Stouten P.F. The de novo design and synthesis of cyclic urea inhibitors of factor Xa: initial SAR studies. Bioorg. Med. Chem. Lett. 8 19 (1998) 2705-2710
44. Gong Y., Pauls H.W., Spada A.P., Czekaj M., Liang G., Chu V., Colussi D.J., Brown K.D., and Gao J. Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa. Bioorg. Med. Chem. Lett. 10 3 (2000) 217-221
45. Guertin K.R., Gardner C.J., Klein S.I., Zulli A.L., Czekaj M., Gong Y., Spada A.P., Cheney D.L., Maignan S., Guilloteau J.P., et al. Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2. Identification of FXV673 as a potent and selective inhibitor with excellent in vivo anticoagulant activity. Bioorg. Med. Chem. Lett. 12 12 (2002) 1671-1674
46. Guilford W.J., Shaw K.J., Dallas J.L., Koovakkat S., Lee W., Liang A., Light D.R., McCarrick M.A., Whitlow M., Ye B., et al. Synthesis, characterization, and structure-activity relationships of amidine-substituted (bis)benzylidene-cycloketone olefin isomers as potent and selective factor Xa inhibitors. J. Med. Chem. 42 26 (1999) 5415-5425
47. He W., Hanney B., Myers M.R., Spada A.P., Brown K., Colussi D., and Chu V. Nonbenzamidine compounds as selective factor Xa inhibitors. Bioorg. Med. Chem. Lett. 10 15 (2000) 1737-1739
48. Jones S.D., Liebeschuetz J.W., Morgan P.J., Murray C.W., Rimmer A.D., Roscoe J.M., Waszkowycz B., Welsh P.M., Wylie W.A., Young S.C., et al. The design of phenylglycine containing benzamidine carboxamides as potent and selective inhibitors of factor Xa. Bioorg. Med. Chem. Lett. 11 5 (2001) 733-736
49. Maduskuie Jr. T.P., McNamara K.J., Ru Y., Knabb R.M., and Stouten P.F. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors. J. Med. Chem. 41 1 (1998) 53-62
50. Maignan S., Guilloteau J.P., Pouzieux S., Choi-Sledeski Y.M., Becker M.R., Klein S.I., Ewing W.R., Pauls H.W., Spada A.P., and Mikol V. Crystal structures of human factor Xa complexed with potent inhibitors. J. Med. Chem. 43 17 (2000) 3226-3232
51. Matter H., Defossa E., Heinelt U., Blohm P.M., Schneider D., Muller A., Herok S., Schreuder H., Liesum A., Brachvogel V., et al. Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa. J. Med. Chem. 45 13 (2002) 2749-2769
52. Ng H.P., Buckman B.O., Eagen K.A., Guilford W.J., Kochanny M.J., Mohan R., Shaw K.J., Wu S.C., Lentz D., Liang A., et al. Design, synthesis, and biological activity of novel factor Xa inhibitors: 4-aryloxy substituents of 2,6-diphenoxypyridines. Bioorg. Med. Chem. 10 3 (2002) 657-666
53. Phillips G., Guilford W.J., Buckman B.O., Davey D.D., Eagen K.A., Koovakkat S., Liang A., McCarrick M., Mohan R., Ng H.P., et al. Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groups. J. Med. Chem. 45 12 (2002) 2484-2493
54. Pinto D.J., Orwat M.J., Wang S., Fevig J.M., Quan M.L., Amparo E., Cacciola J., Rossi K.A., Alexander R.S., Smallwood A.M., et al. Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2′-(methylsulfonyl)-[1,1′ -biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 44 4 (2001) 566-578
55. Pruitt J.R., Pinto D.J., Estrella M.J., Bostrom L.L., Knabb R.M., Wong P.C., Wright M.R., and Wexler R.R. Isoxazolines and isoxazoles as factor Xa inhibitors. Bioorg. Med. Chem. Lett. 10 8 (2000) 685-689
56. Quan M.L., Liauw A.Y., Ellis C.D., Pruitt J.R., Carini D.J., Bostrom L.L., Huang P.P., Harrison K., Knabb R.M., Thoolen M.J., et al. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors 1. J. Med. Chem. 42 15 (1999) 2752-2759
57. Quan M.L., Ellis C.D., Liauw A.Y., Alexander R.S., Knabb R.M., Lam G., Wright M.R., Wong P.C., and Wexler R.R. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors 2. J. Med. Chem. 42 15 (1999) 2760-2773
58. Renatus M., Bode W., Huber R., Sturzebecher J., and Stubbs M.T. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase. J. Med. Chem. 41 27 (1998) 5445-5456
59. Sagi K., Nakagawa T., Yamanashi M., Makino S., Takahashi M., Takayanagi M., Takenaka K., Suzuki N., Oono S., Kataoka N., et al. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids. J. Med. Chem. 46 10 (2003) 1845-1857
60. Shaw K.J., Guilford W.J., Griedel B.D., Sakata S., Trinh L., Wu S., Xu W., Zhao Z., and Morrissey M.M. Benzimidazole-based fXa inhibitors with improved thrombin and trypsin selectivity. Bioorg. Med. Chem. Lett. 12 9 (2002) 1311-1314
61. Smallheer J.M., Alexander R.S., Wang J., Wang S., Nakajima S., Rossi K.A., Smallwood A., Barbera F., Burdick D., Luettgen J.M., et al. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa. Bioorg. Med. Chem. Lett. 14 21 (2004) 5263-5267
62. Verner E., Katz B.A., Spencer J.R., Allen D., Hataye J., Hruzewicz W., Hui H.C., Kolesnikov A., Li Y., Luong C., et al. Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa. J. Med. Chem. 44 17 (2001) 2753-2771
63. Wiley M.R., Weir L.C., Briggs S., Bryan N.A., Buben J., Campbell C., Chirgadze N.Y., Conrad R.C., Craft T.J., Ficorilli J.V., et al. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity. J. Med. Chem. 43 5 (2000) 883-899
64. Wu S., Guilford W.J., Chou Y.L., Griedel B.D., Liang A., Sakata S., Shaw K.J., Trinh L., Xu W., Zhao Z., et al. Design and synthesis of aminophenol-based factor Xa inhibitors. Bioorg. Med. Chem. Lett. 12 9 (2002) 1307-1310
65. Zhao Z., Arnaiz D.O., Griedel B., Sakata S., Dallas J.L., Whitlow M., Trinh L., Post J., Liang A., Morrissey M.M., et al. Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors. Bioorg. Med. Chem. Lett. 10 9 (2000) 963-966
66. Nazare M., Will D.W., Matter H., Schreuder H., Ritter K., Urmann M., Essrich M., Bauer A., Wagner M., Czech J., et al. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography. J. Med. Chem. 48 14 (2005) 4511-4525
67. Cui J., Crich D., Wink D., Lam M., Rheingold A.L., Case D.A., Fu W., Zhou Y., Rao M., Olson A.J., et al. Design and synthesis of highly constrained factor Xa inhibitors: amidine-substituted bis(benzoyl)-diazepan-2-ones and bis(benzylidene)-bis(gem-dimethyl)cycloketones. Bioorg. Med. Chem. 11 16 (2003) 3379-3392
68. Rai R., Kolesnikov A., Li Y., Young W.B., Leahy E., Sprengeler P.A., Verner E., Shrader W.D., Burgess-Henry J., Sangalang J.C., et al. Development of potent and selective factor Xa inhibitors. Bioorg. Med. Chem. Lett. 11 14 (2001) 1797-1800
69. Good A.C., Hermsmeier M.A., and Hindle S.A. Measuring CAMD technique performance: a virtual screening case study in the design of validation experiments. J. Comput. Aided Mol. Des. 18 7-9 (2004) 529-536
70. Yap C.W., and Chen Y.Z. Prediction of cytochrome P450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines. J. Chem. Inf. Model 45 4 (2005) 982-992
71. Molnar L., and Keseru G.M. A neural network based virtual screening of cytochrome P450 3A4 inhibitors. Bioorg. Med. Chem. Lett. 12 3 (2002) 419-421
72. CambridgeSoft Corporation. ChemDraw In., 7.0.1 edn. (2002), CambridgeSoft Corporation, Cambridge, MA, USA
73. Accelrys: DS ViewPro. In., 5.0 edn. San Diego, CA: Accelrys, 2002.
74. Willett P., Barnard J.M., and Downs G.M. Chemical similarity searching. J. Chem. Inf. Comp. Sci. 38 (1998) 983-996
75. Todeschini R., and Consonni V. Handbook of Molecular Descriptors (2000), Wiley-VCH, Weinheim
76. Hu J.Y., and Aizawa T. Quantitative structure-activity relationships for estrogen receptor binding affinity of phenolic chemicals. Water Res. 37 6 (2003) 1213-1222
77. Xue Y., Li Z.R., Yap C.W., Sun L.Z., Chen X., and Chen Y.Z. Effect of molecular descriptor feature selection in support vector machine classification of pharmacokinetic and toxicological properties of chemical agents. J. Chem. Inform. Comp. Sci. 44 (2004) 1630-1638
78. Yu H., Yang J., Wang W., and Han J. Discovering compact and highly discriminative features or feature combinations of drug activities using support vector machines. IEEE Computer Society Bioinformatics Conference (CSB'03). Stanford, CA (2003) 220-228
79. Guyon I., Weston J., Barnhill S., and Vapnik V. Gene selection for cancer classification using support vector machines. Mach. Learn. 46 1-3 (2002) 389-422
80. Degroeve S., De Baets B., Van de Peer Y., and Rouzé P. Feature subset selection for splice site prediction. Bioinformatics 18 (2002) S75-S83
81. Furey T.S., Cristianini N., Duffy N., Bednarski D.W., Schummer M., and Haussler D. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 16 10 (2000) 906-914
82. Furlanello C., Serafini M., Merler S., and Jurman G. An accelerated procedure for recursive feature ranking on microarray data. Neural Netw. 16 5/6 (2003) 641-648
83. Trotter M.W.B., Buxton B.F., and Holden S.B. Support vector machines in combinatorial chemistry. Meas. Control 34 8 (2001) 235-239
84. Burbidge R., Trotter M., Buxton B., and Holden S. Drug design by machine learning: support vector machines for pharmaceutical data analysis. Comp. Chem. 26 1 (2001) 5-14
85. Czerminski R., Yasri A., and Hartsough D. Use of support vector machine in pattern classification: application to QSAR studies. Quant. Struct.-Activity Relationships 20 3 (2001) 227-240
86. Fix E., and Hodges J.L. Discriminatory Analysis: Non-Parametric Discrimination: Consistency Properties (1951), USAF School of Aviation Medicine, Randolph Field, Texas
87. Parzen E. On estimation of a probability density function and mode. Ann. Math. Stat. 33 (1962) 1065-1076
88. Cacoullos T. Estimation of a multivariate density. Ann. Inst. Stat. Math. 18 (1966) 179-189
89. Carnahan B., Meyer G., and Kuntz L.-A. Comparing statistical and machine learning classifiers: alternatives for predictive modeling in human factors research. Hum. Factors 45 (2003) 408-423
90. Baldi P., Brunak S., Chauvin Y., Andersen C.A., and Nielsen H. Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics 16 5 (2000) 412-424
91. Roulston J.E. Screening with tumor markers. Mol. Pharmacol. 20 (2002) 153-162
92. Matthews B.W. Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochim. Biophys. Acta 405 2 (1975) 442-451
93. Rao M.S., and Olson A.J. Modelling of factor Xa-inhibitor complexes: a computational flexible docking approach. Proteins 34 2 (1999) 173-183
94. Taha M.O., Qandil A.M., Zaki D.D., and AlDamen M.A. Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling. Eur. J. Med. Chem. 40 7 (2005) 701-727
95. Bohm M., St rzebecher J., and Klebe G. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J. Med. Chem. 42 3 (1999) 458-477
96. Yee Y.K., Tebbe A.L., Linebarger J.H., Beight D.W., Craft T.J., Gifford-Moore D., Goodson Jr. T., Herron D.K., Klimkowski V.J., Kyle J.A., et al. N(2)-Aroylanthranilamide inhibitors of human factor Xa. J. Med. Chem. 43 5 (2000) 873-882
97. Roy K., De A.U., and Sengupta C. QSAR of human factor Xa inhibitor N2-aroylanthranilamides using principal component factor analysis. Drug Des. Discov. 18 1 (2002) 23-31
98. Roy K., De A.U., and Sengupta C. QSAR with electrotopological state atom index: human factor Xa inhibitor N2-aroylanthranilamides. Drug Des. Discov. 18 1 (2002) 33-43
99. Li H., Ung C.Y., Yap C.W., Xue Y., Li Z.R., Cao Z.W., and Chen Y.Z. Prediction of genotoxicity of chemical compounds by statistical learning methods. Chem. Res. Toxicol. 18 6 (2005) 1071-1080
100. H. Li, C.Y. Ung, C.W. Yap, Y. Xue, Z.R. Li, Y.Z. Chen. Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. J. Mol. Graph Model (2006).
101. Chapelle O., Vapnik V., Bousquet O., and Mukherjee S. Choosing multiple parameters for support vector machines. Mach. Learn. 46 1-3 (2002) 131-159
102. Labute P. A widely applicable set of descriptors. J. Mol. Graph Model 18 4/5 (2000) 464-477